secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-05-19T13:00:16+00:00
Accession:  0001493152-26-024365
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine LPCN 1154 Phase 3 data accepted for oral presentation at 2026 ASCP meeting
--------------------------------------------------------------------------------

- Phase 3 data for LPCN 1154 (oral brexanolone) for postpartum depression accepted for oral and poster presentation at ASCP Annual Meeting May 26-29, 2026 in Miami, FL.
- Oral presentation by Benjamin Bruno, PhD, VP Clinical Development, on May 26, 2026 at 3:20 PM ET; poster session on May 27.
- LPCN 1154 is an oral non-SSRI neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors.
- Potential for acute stabilization of PPD symptoms with low CNS depressant side effects, no intensive monitoring required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226024365/0001493152-26-024365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226024365/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer